Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Acute pancreatitis: an emerging presentation for autoimmune pancreatitis in patients with inflammatory bowel disease.

Literature DB >> 20574503

Acute pancreatitis: an emerging presentation for autoimmune pancreatitis in patients with inflammatory bowel disease.

Marc Barthet¹.

Abstract

Entities: Disease Species

Year: 2009 PMID： 20574503 PMCID： PMC2886392

Source DB: PubMed Journal: Gastroenterol Hepatol (N Y) ISSN： 1554-7914

× No keyword cloud information.

35 in total

1. Frequency and characteristics of pancreatitis in patients with inflammatory bowel disease.

Authors: Marc Barthet; Nathalie Lesavre; Sophie Desplats; Michel Panuel; Mohamed Gasmi; Jean-Paul Bernard; Jean-Charles Dagorn; Jean-Charles Grimaud
Journal: Pancreatology Date: 2006-07-13 Impact factor: 3.996

2. Autoimmune pancreatitis: increasing evidence for a clinical entity with various patterns.

Authors: José Sahel; Marc Barthet; Mohamed Gasmi
Journal: Eur J Gastroenterol Hepatol Date: 2004-11 Impact factor: 2.566

3. Perinuclear anti-neutrophil cytoplasmic antibodies are spontaneously produced by mucosal B cells of ulcerative colitis patients.

Authors: S R Targan; C J Landers; L Cobb; R P MacDermott; A Vidrich
Journal: J Immunol Date: 1995-09-15 Impact factor: 5.422

4. High serum IgG4 concentrations in patients with sclerosing pancreatitis.

Authors: H Hamano; S Kawa; A Horiuchi; H Unno; N Furuya; T Akamatsu; M Fukushima; T Nikaido; K Nakayama; N Usuda; K Kiyosawa
Journal: N Engl J Med Date: 2001-03-08 Impact factor: 91.245

Review 5. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis.

Authors: K Yoshida; F Toki; T Takeuchi; S Watanabe; K Shiratori; N Hayashi
Journal: Dig Dis Sci Date: 1995-07 Impact factor: 3.199

6. Clinical study of chronic pancreatitis with focal irregular narrowing of the main pancreatic duct and mass formation: comparison with chronic pancreatitis showing diffuse irregular narrowing of the main pancreatic duct.

Authors: Tokio Wakabayashi; Yukimitsu Kawaura; Yoshitake Satomura; Tomoharu Fujii; Yoshiharu Motoo; Takashi Okai; Norio Sawabu
Journal: Pancreas Date: 2002-10 Impact factor: 3.327

3. Role of pharmacoepidemiology studies in addressing pharmacovigilance questions: a case example of pancreatitis risk among ulcerative colitis patients using mesalazine.

Authors: Leo Russo; Gary Schneider; Margarita Hauser Gardiner; Stephan Lanes; Paul Streck; Susan Rosen
Journal: Eur J Clin Pharmacol Date: 2014-03-11 Impact factor: 2.953

3 in total

Acute pancreatitis: an emerging presentation for autoimmune pancreatitis in patients with inflammatory bowel disease.

1. Frequency and characteristics of pancreatitis in patients with inflammatory bowel disease.

2. Autoimmune pancreatitis: increasing evidence for a clinical entity with various patterns.

3. Perinuclear anti-neutrophil cytoplasmic antibodies are spontaneously produced by mucosal B cells of ulcerative colitis patients.

4. High serum IgG4 concentrations in patients with sclerosing pancreatitis.

Review 5. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis.

6. Clinical study of chronic pancreatitis with focal irregular narrowing of the main pancreatic duct and mass formation: comparison with chronic pancreatitis showing diffuse irregular narrowing of the main pancreatic duct.

7. Multiple pancreatic masses associated with autoimmunity.

8. Idiopathic pancreatitis associated with inflammatory bowel disease.

9. Pancreatitis associated with duodenal Crohn's disease.

10. Drug induced acute pancreatitis: incidence and severity.

1. Hepatopancreatobiliary manifestations of inflammatory bowel disease.

Review 2. Pancreatic disorders in inflammatory bowel disease.

3. Role of pharmacoepidemiology studies in addressing pharmacovigilance questions: a case example of pancreatitis risk among ulcerative colitis patients using mesalazine.